EP2601314A4 - Prognostic gene signatures for non-small cell lung cancer - Google Patents

Prognostic gene signatures for non-small cell lung cancer

Info

Publication number
EP2601314A4
EP2601314A4 EP11813988.0A EP11813988A EP2601314A4 EP 2601314 A4 EP2601314 A4 EP 2601314A4 EP 11813988 A EP11813988 A EP 11813988A EP 2601314 A4 EP2601314 A4 EP 2601314A4
Authority
EP
European Patent Office
Prior art keywords
lung cancer
small cell
cell lung
gene signatures
prognostic gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11813988.0A
Other languages
German (de)
French (fr)
Other versions
EP2601314A1 (en
Inventor
Fadia Saad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Med Biogene Inc
Original Assignee
Med Biogene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Biogene Inc filed Critical Med Biogene Inc
Publication of EP2601314A1 publication Critical patent/EP2601314A1/en
Publication of EP2601314A4 publication Critical patent/EP2601314A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
EP11813988.0A 2010-08-04 2011-08-04 Prognostic gene signatures for non-small cell lung cancer Withdrawn EP2601314A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37069010P 2010-08-04 2010-08-04
PCT/CA2011/000891 WO2012016332A1 (en) 2010-08-04 2011-08-04 Prognostic gene signatures for non-small cell lung cancer

Publications (2)

Publication Number Publication Date
EP2601314A1 EP2601314A1 (en) 2013-06-12
EP2601314A4 true EP2601314A4 (en) 2013-12-11

Family

ID=45558885

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11813988.0A Withdrawn EP2601314A4 (en) 2010-08-04 2011-08-04 Prognostic gene signatures for non-small cell lung cancer

Country Status (3)

Country Link
US (1) US20120258878A1 (en)
EP (1) EP2601314A4 (en)
WO (1) WO2012016332A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110238322A1 (en) * 2008-11-03 2011-09-29 Precision Therapeutics, Inc. Methods of simulating chemotherapy for a patient
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
EP2965086A4 (en) * 2013-03-09 2017-02-08 Harry Stylli Methods of detecting prostate cancer
AU2014346788B8 (en) 2013-11-06 2021-01-28 Arizona Board Of Regents On Behalf Of The Unviersity Of Arizona Method for subtyping lymphoma types by means of expression profiling
US10138522B2 (en) 2014-02-24 2018-11-27 Vanderbilt University Identification of cattle at risk of high altitude pulmonary hypertension
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
WO2016109546A2 (en) * 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
CN107034282B (en) * 2017-05-10 2020-04-07 西北农林科技大学 RFLP method for rapidly detecting cattle KCNJ12 gene SNP and application thereof
CN109900461B (en) * 2019-02-27 2020-12-01 东软医疗***股份有限公司 Method and device for testing safety of CT rotating plate
US20230044602A1 (en) * 2019-12-20 2023-02-09 EDWARD Via COLLEGE OF OSTEOPATHIC MEDICINE Cancer signatures, methods of generating cancer signatures, and uses thereof
CA3201466A1 (en) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
GB202104422D0 (en) * 2021-03-29 2021-05-12 Orre Lukas Methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOUTROS PAUL C ET AL: "Prognostic gene signatures for non-small-cell lung cancer.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 24 FEB 2009, vol. 106, no. 8, 24 February 2009 (2009-02-24), pages 2824 - 2828, XP002714065, ISSN: 1091-6490 *
CHEN HSUAN-YU ET AL: "A five-gene signature and clinical outcome in non-small-cell lung cancer", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 356, no. 1, 4 January 2007 (2007-01-04), pages 11 - 20, XP009086044, ISSN: 1533-4406, DOI: 10.1056/NEJMOA060096 *
J. SUBRAMANIAN ET AL: "Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?", JNCI JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 102, no. 7, 7 April 2010 (2010-04-07), pages 464 - 474, XP055073612, ISSN: 0027-8874, DOI: 10.1093/jnci/djq025 *
See also references of WO2012016332A1 *
YAN LU ET AL: "A gene expression signature predicts survival of patients with stage I non- small cell lung cancer", PLOS MEDICINE, PUBLIC LIBRARY OF SCIENCE, US, vol. 3, no. 12, 26 December 2006 (2006-12-26), pages 2229 - 2242, XP002636310, ISSN: 1549-1676, DOI: 10.1371/JOURNAL.PMED.0030467 *

Also Published As

Publication number Publication date
US20120258878A1 (en) 2012-10-11
WO2012016332A1 (en) 2012-02-09
EP2601314A1 (en) 2013-06-12

Similar Documents

Publication Publication Date Title
EP2601314A4 (en) Prognostic gene signatures for non-small cell lung cancer
EP2591126A4 (en) Gene signatures for cancer prognosis
IL210026A0 (en) Serum or plasma microrna as biomarkers for non-small cell lung cancer
HK1193637A1 (en) Biomarkers for lung cancer
WO2012030840A9 (en) Gene signatures for cancer diagnosis and prognosis
ZA201203010B (en) Diagnostic methods for determining prognosis of non-small cell lung cancer
EP2288741A4 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
HUE036585T2 (en) Multigene prognostic assay for lung cancer
PL2576837T3 (en) Prostate cancer associated circulating nucleic acid biomarkers
EP2683643A4 (en) Prostate cancer cell lines, gene signatures and uses thereof
WO2011163332A9 (en) Methods for detecting cancer
EP2558854A4 (en) Breast cancer associated circulating nucleic acid biomarkers
PL2768985T3 (en) Colorectal cancer associated circulating nucleic acid biomarkers
IL235459A0 (en) Method for treating non-small cell lung cancer
EP2744919A4 (en) Gene signatures for lung cancer prognosis and therapy selection
EP2529223A4 (en) Biomarkers for circulating tumor cells
WO2012012225A9 (en) Predicting cancer outcome
HK1208058A1 (en) Diagnostic gene marker panel for colorectal cancer
EP2657346A4 (en) Method for detecting cancer cell
GB0811413D0 (en) Gene expression signatures for lung cancers
EP2531619A4 (en) Hypoxia-related gene signatures for cancer classification
ZA201309254B (en) Method for treating non-small cell lung cancer
IL227419A0 (en) Prognostic signature for colorectal cancer recurrence
WO2012030896A9 (en) Methods for treatment of non-small cell lung cancer
EP2521730A4 (en) Gene biomarkers of lung function

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SAAD, FADIA

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20131030BHEP

Ipc: G01N 33/53 20060101ALI20131030BHEP

Ipc: C40B 40/08 20060101ALI20131030BHEP

Ipc: C12Q 1/68 20060101AFI20131030BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20131112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140611